Mucoangin (Ambroxol Hydrochloride)

Ambroxol hydrochloride stimulates surfactant production by type II pneumocytes and hydrolyzes mucopolysaccharide fibers, which reduces mucus viscosity. This action enhances mucociliary clearance and promotes expectoration, while also providing a local anti‑inflammatory effect on the respiratory epithelium.

The appropriate dose of Mucoangin is determined by the prescribing healthcare professional based on the patient’s age, condition severity, and renal function. Dosage instructions are provided on the prescription label and should be followed exactly as directed.

Safety data for Ambroxol hydrochloride in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made in consultation with a qualified healthcare provider.

To place an order, submit an enquiry on the Mucoangin product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mucoangin (ambroxol) differs from agents such as guaifenesin by directly stimulating surfactant secretion and hydrolyzing mucus fibers, which can result in faster mucus thinning. It also possesses local anti‑inflammatory properties, whereas many other expectorants primarily act by increasing airway fluid volume.

Mucoangin should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture, heat and direct sunlight, and ensure the container is tightly closed when not in use.

Mucoangin is administered orally via the oromucosal route. The tablet or liquid is taken as directed by the prescriber, usually with a glass of water, and can be taken with or without food unless otherwise specified.

Serious adverse reactions, although rare, include allergic responses such as urticaria, angioedema, or anaphylaxis, as well as severe skin conditions like Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience any signs of a severe hypersensitivity reaction.

Mucoangin should be avoided in individuals with a known hypersensitivity to ambroxol or any of the product’s excipients. Caution is also advised for patients with severe renal impairment, and it should be used only after careful evaluation in pregnant or breastfeeding women.